PMID- 22869887
OWN - NLM
STAT- MEDLINE
DCOM- 20121203
LR  - 20220409
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 30
IP  - 27
DP  - 2012 Sep 20
TI  - International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered 
      utility in the modern era.
PG  - 3383-8
LID - 10.1200/JCO.2011.41.0910 [doi]
AB  - PURPOSE: The International Prognostic Score (IPS) is the most widely used risk 
      stratification index for Hodgkin's lymphoma (HL). It is based on patients treated 
      before 1992 and predicts 5-year freedom from progression (FFP) and overall 
      survival (OS) ranging from 42% to 84% and 56% to 89%, respectively. The IPS has 
      not been validated in a recently treated population in which outcomes have 
      improved compared with historic results. PATIENTS AND METHODS: By using the 
      British Columbia Cancer Agency Lymphoid Cancer Database, we identified all 
      patients age >/= 16 years newly diagnosed with advanced-stage HL (stage III to IV, 
      or stage I to II with "B" symptoms or bulky disease >/= 10 cm) from 1980 to 2010, 
      treated with curative intent with doxorubicin, bleomycin, vinblastine, and 
      dacarbazine (ABVD) or an ABVD-equivalent regimen with complete clinical 
      information. RESULTS: In all, 740 patients were identified. Five-year FFP and OS 
      were 78% and 90%, respectively. The IPS was prognostic for both FFP (P < .001) 
      and OS (P < .001), with 5-year FFP ranging from 62% to 88% and 5-year OS ranging 
      from 67% to 98%. Analysis limited to patients age 16 to 65 years (n = 686) 
      demonstrated a narrower range of outcomes, with 5-year FFP ranging from 70% to 
      88% and 5-year OS ranging from 73% to 98%. CONCLUSION: The IPS remains prognostic 
      for advanced-stage HL, but the range of outcomes has narrowed considerably. This 
      improvement in outcome with ABVD should be acknowledged before consideration of 
      alternate initial therapies and when comparing results from current trials with 
      those of historic controls.
FAU - Moccia, Alden A
AU  - Moccia AA
AD  - British Columbia Cancer Agency and University of British Columbia, Vancouver, 
      British Columbia, Canada.
FAU - Donaldson, Jane
AU  - Donaldson J
FAU - Chhanabhai, Mukesh
AU  - Chhanabhai M
FAU - Hoskins, Paul J
AU  - Hoskins PJ
FAU - Klasa, Richard J
AU  - Klasa RJ
FAU - Savage, Kerry J
AU  - Savage KJ
FAU - Shenkier, Tamara N
AU  - Shenkier TN
FAU - Slack, Graham W
AU  - Slack GW
FAU - Skinnider, Brian
AU  - Skinnider B
FAU - Gascoyne, Randy D
AU  - Gascoyne RD
FAU - Connors, Joseph M
AU  - Connors JM
FAU - Sehn, Laurie H
AU  - Sehn LH
LA  - eng
PT  - Journal Article
DEP - 20120806
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 11056-06-7 (Bleomycin)
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - ABVD protocol
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols
MH  - Bleomycin
MH  - British Columbia/epidemiology
MH  - Dacarbazine
MH  - Doxorubicin
MH  - Female
MH  - Follow-Up Studies
MH  - Hodgkin Disease/*diagnosis/drug therapy/*mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Prognosis
MH  - Reproducibility of Results
MH  - Survival Analysis
MH  - Vinblastine
EDAT- 2012/08/08 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/08/08 06:00
PHST- 2012/08/08 06:00 [entrez]
PHST- 2012/08/08 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - JCO.2011.41.0910 [pii]
AID - 10.1200/JCO.2011.41.0910 [doi]
PST - ppublish
SO  - J Clin Oncol. 2012 Sep 20;30(27):3383-8. doi: 10.1200/JCO.2011.41.0910. Epub 2012 
      Aug 6.